Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
Globe Newswire•10/11/2026•16:16 ET
0
Key Highlights
- ➤CTIM-76 weekly dosing delivered 22% confirmed ORR and 56% confirmed DCR in PROC
- ➤Median PFS reached 5.6 months at biologically active weekly doses
- ➤Cash $34.4M at September 30, 2026, expected to fund operations into early Q4 2027
- ➤CTIM-76 Q3W dose escalation advanced to 420 µg after 280 µg DLT assessment
- ➤Phase 1b initiation expected Q1 2027, with initial Q3W efficacy data in Q2 2027
Expert Statements
Martin Lehr, Chief Executive Officer of Context Therapeutics
“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy”
Martin Lehr, Chief Executive Officer of Context Therapeutics
“Our Phase 1b strategy is to evaluate CTIM-76 in patients with no more than five prior lines of therapy.”
Martin Lehr, Chief Executive Officer of Context Therapeutics
“These less heavily pretreated patients generally have lower tumor burden and better T cell fitness,(2) providing a rationale to evaluate whether treatment in this population, together with Q3W dosing, can deliver greater clinical benefit and improved tolerability.(3)”
Martin Lehr, Chief Executive Officer of Context Therapeutics
“We view the results to date as an initial benchmark, with Phase 1b providing an opportunity to further define CTIM-76’s clinical potential.”
CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months
Dose escalation to 420 µg every three weeks is ongoing following completion of the DLT assessment period at 280 µg
Get started
Create a free account to read the full story.